Difficulty of weaning off the cardiopulmonary bypass (CPB) due to postcardiotomy heart failure is a serious problem in cardiac surgeries. Levosimendan, a calcium sensitizer, has been shown to expert a positive inotropic effect without disturbing the energy balance of the heart. Levosimendan combines with troponin C in the myocardium and stabilizes the troponin C-calcium complex, without increasing th intracellular calcium level. Its action produces improved myocardial contractility and cardiac output without increasing myocardial oxygen demand. This report describes the successful use of levosimendan infusion in two cases having difficulty in weaning from CPB pump during coroner artery bypass grafting (CABG) surgery. First case scheduled for CABG surgery.
BACKGROUND
Vasodilator and inotropic drugs and intra-aortic balloon pump are used to provide tissue perfusion and weaning from cardiopulmonary bypass (CPB) in the perioperative period ( 1 ). Levosimendan increases the sensitivity of myofilaments to calcium by binding to cardiac troponin C and also causes vasodilatation in systemic arterial and venous capacitance vessels by opening ATP-sensitive potassium-channels in vascular smooth muscles. Furthermore, levosimendan does not cause any increase in myocardial oxygen demand by reducing cardiac work load effectively ( 2 ). Here we evaluated two cases who failed to wean from CPB with their low cardiac outputs despite the support of the intraaortic baloon pump but successfully weaned off with the addition of levosimendan treatment.
CASE 1
The medical history of 41-years old male patient scheduled for coronary artery bypass grafting surgery includes Type I DM and femoropopliteal bypass surgery. Transthoracic echocardiography revealed; left ventricle end diastolic diameter: 68 mm; left ventricle end systolic diameter: 55 mm; left ventricle end diastolic volume: 203 mL; left ventricle end systolic volume: 120 mL, ejection fraction: 35% and a thrombus in the anteroapical region of the LV. Euroscore was scored as 4. No premedication was performed and the following drugs were given intravenously for induction: lidocaine 1 mg. 
DISCUSSION
Difficulty of weaning off the cardiopulmonary bypass due to postcardiotomy heart failure is a serious problem in cardiac surgeries ( 3 , 4 , 5 ). In heart surgery, it was found that inotropic drugs were needed in 71 to 100% of cases with ejection fraction (EF) less than 46% in order to be weaned off the cardiopulmonary bypass ( 6 ). In addition to pharmacotherapy, the use of intra-aortic balloon pump, and delayed sternum closure is suggested in some studies to support circulation ( 7 ).
Both β-adrenergic agonists and phosphodiesterase inhibitors increase intracellular cyclic adenosine monophosphate, either via an increase in production (β-adrenergic agonists) or by inhibiting degradation (phosphodiesterase inhibitors). The available data on use of dopamine, dobutamine, and dopexamine in the postcardiac surgery period show that they produce an increase in cardiac output. However, there is an increase in myocardial oxygen requirement and an increased risk for postoperative myocardial infarction ( 8 , 9 , 10 ). Despite the dopamine, dobutamine and adrenalin support, failure in weaning off CPB led to the usage of intraaortic baloon pump in both two cases with low ejection fraction. In these cases, we couldn't use noradrenaline and milrinon because we didn't have these drugs so we had to use levosimendan although it's expensive and restricted.
Levosimendan is a novel inotropic agent having a different pharmacological profile. It provides good cardiac performance without causing an increased myocardial oxygen demand or any change in myocardial metabolism ( 11 ).
Levosimendan is a promising new calcium sensitizer that mproves hemodynamics in patients with acute heart failure. Its inotropic effect is mediated by calcium concentrationdependent stabilization of conformational changes in troponin C during systole, causingsensitization of the contractile apparatus to calcium ions; its vasodilator effect is linked to the activation of ATP-dependent potassium channels. Anti-ischemic properties can also be attributed to the latter mechanism. Hence, levosimendan enhances cardiac performance without advers effects on diastolic function. Levosimendan also reduces preload and afterload while improving both coronary blood flow and cariac function in stunned myocardium ( 2 , 12 )
It is known that levosimendan infusion after cardiac surgery provides improvement in hemodynamic parameters by increasing left ventricular functions and is effective in patients having difficulty to wean of from cardiopulmonary bypass ( 13 ). In multicenter RUSSLAN study ( 14 ), in patients with heart dysfunction due to myocardial infarction, three different levosimendan doses were compared with placebo; Levosimendan doses administered to the patients were as follows: 24 µgkg -1 bolus infusion followed by 0.4 µg.kg -1 infusion; 24 µg.kg -1 bolus infusion followed by 0.2 µg.kg -1 infusion; 12 µgkg -1 bolus infusion followed by 0.2 µg.kg -1 infusion; 6 µgkg -1 bolus infusion followed by 0.1 µg.kg -1 infusion. In high dose levosimendan (24 µg.kg -1 bolus infusion followed by 0.4 µg.kg.dk -1 infusion) group the incidence of hypotension and ischemia was found to be increased compared to other groups. Nevertheless, it was determined that dose-response relationship was not significant and levosimendan was well tolerated in acute myocardial infarction. The results of these dose-dependent study showed the relatively wide therapeutic index of levosimendan ( 14 ).
In randomized, double-blind LIDO study ( 12 ), levosimendan 24 µgkg -1 bolus infusion followed by 0.1 µg.kg -1 infusion and dobutamine 5 µg.kg.dk -1 infusion for 24 hours were administered to 203 patients with EF less than 35%, CI 2.5/L/dk/m 2 and PCWP less than 15 mmHg. Infusion rates were doubled at the end 2 hours when drug response was found inadequate. An increase of cardiac output more than 30 % and pulmonary capillary wedge pressure decrease more than 25 % were considered as hemodynamic improvement criterion. As a result, it has shown that increase of cardiac output and decrease of pulmonary wedge pressure were statistically higher in levosimendan group compared to dobutamine group ( 12 ).
In both of our cases, levosimendan 12 µgkg -1 bolus infusion followed by 0.1 µg.kg -1 infusion was administered because of the inadequate hemodynamic improvement with
The Effect Of Levosimendan Following Cardiac Surgery: Two Case Reports pharmacological inotropic support and use of intra-aortic balloon pump and levosimendan infusion was maintained for 20 hours. Our levosimendan dose is similar to the dose in LIDO study.
Underlying systemic disease, surgical intervention, invasive monitorization, surgical stress and systemic inflammatory response are important factors that contribute the development of nosocomial infection after cardiac surgery in intensive care follow up period. Our first case was intubated again in the third day in intensive care unit due to postoperative nosocomial infection and associated multiorgan failure requiring mechanical ventilation support. Despite all inotropic support the patient died from irreversible cardiac and multiorgan failure after 32 days postoperatively. We assume that levosimendan infusion improves the hemodynamic parameters and also effective during the weaning off stage in case with low ejection fraction and in cases where inotropic agents or intra-aortic balloon pump support are inadequate. 
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